Serum anti-p53 autoantibodies in angiosarcoma

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Angiosarcoma lacks a reliable biomarker for monitoring patient status.
• Elevated serum anti-p53 antibody (Ab) levels are observed in various cancers, indicating potential as a tumor biomarker.

Purpose of the Study:

• To evaluate the utility of serum anti-p53 Ab as a biomarker for diagnosing and monitoring angiosarcoma.
• To assess the correlation between serum anti-p53 Ab levels and the clinical course of angiosarcoma patients.

Main Methods:

• Histological diagnosis of cutaneous angiosarcoma in 19 patients.
• Comparison of p53 protein expression in tumor tissues versus normal skin.
• Quantification of serum anti-p53 Ab levels in patients and 30 healthy controls before and after therapy.

Main Results:

• Increased p53 protein expression was found in angiosarcoma tissues.
• Serum anti-p53 Ab levels were significantly elevated in angiosarcoma patients compared to controls.
• Rising Ab levels correlated with disease progression, while decreasing levels indicated treatment response.

Conclusions:

• Serum anti-p53 Ab is a potential diagnostic biomarker for angiosarcoma.
• Serum anti-p53 Ab levels reflect the clinical course and can serve as a prognostic biomarker for angiosarcoma patients.